01:21 PM EDT, 09/02/2025 (MT Newswires) -- AbbVie ( ABBV ) said Tuesday that the Health Canada has approved Elahere for adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.

The approval came after the drug showed statistically significant and clinically meaningful improvements in overall survival compared with chemotherapy alone for patients with platinum-resistant ovarian cancer, the company said.

Price: 211.16, Change: +0.75, Percent Change: +0.36